BCL2 and B-cell chronic lymphocytic leukemia: Autologous CD19-directed CAR T-cell therapy lisocabtagene maraleucel (liso-cel) recently gained FDA approval on 14 March 2024 for use in patients with CLL, which has progressed following BTK inhibitors and BCL-2 inhibitors, based on the TRANSCEND-CLL-004 study (Phase I/II) [30].